A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT06425549. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Study identification
- NCT ID
- NCT06425549
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Interventions
- bimekizumab Drug
- placebo Drug
- ustekinumab Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2024
- Primary completion
- Aug 20, 2028
- Completion
- Nov 7, 2030
- Last update posted
- May 7, 2026
2024 – 2030
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ps0021 50162 | Fountain Valley | California | 92708 | Active, not recruiting |
| Ps0021 50161 | Los Angeles | California | 90045 | Active, not recruiting |
| Ps0021 50196 | Northridge | California | 91325 | Completed |
| Ps0021 50581 | Miami | Florida | 33165 | Withdrawn |
| Ps0021 50344 | Indianapolis | Indiana | 46250 | Active, not recruiting |
| Ps0021 50599 | Kew Gardens | New York | 11415 | Withdrawn |
| Ps0021 50084 | Charleston | South Carolina | 29425 | Active, not recruiting |
| Ps0021 50201 | Arlington | Texas | 76011 | Completed |
| Ps0021 50355 | Dallas | Texas | 75235 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06425549, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06425549 live on ClinicalTrials.gov.